16th Annual NATA Symposium

16th Annual NATA Symposium, Prague 2015The 16th Annual NATA Symposium on Patient Blood Management, Haemostasis and Thrombosis will take place at the Prague Congress Centre in Prague, Czech Republic, on April 16-17, 2015.

The first announcement can be downloaded in PDF or Powerpoint format. A preliminary version of the scientific programme will be released shortly.

The deadline for abstract submission is December 19, 2014. Please click on the link to download an abstract submission form

More information

Follow NATA on LinkedIn and Twitter

Join NATA's goup on LinkedIn and follow NATA on Twitter (@NATAforum) to receive the latest news on patient blood management, haemostasis and thrombosis, and to participate in discussions with colleagues in the field.
LinkedIn Group / Twitter

News from the Industry: White Paper – Red Cell Salvage: Current Status

Intraoperative Red Cell Salvage (RCS) was introduced in the early 1980s and rapidly gained clinical acceptance. Early RCS was done without cell washing, but washed RCS became the standard of care in cardiac surgery and other procedures.

RCS gained popularity because it did not carry the risk of transfusion-transmitted diseases, notably HIV and hepatitis B and C, and decreased demand for allogeneic blood. While both of these benefits are still true today, the increased safety profile of allogeneic transfusion as well as the presence of stable blood inventories have diminished their importance.

Nevertheless, strong clinical and economic reasons remain to use RCS. This white paper addresses these issues.
Read more on this

News

Antidote for rapid reversal of Pradaxa® (dabigatran etexilate) progresses into next stage of clinical investigation with study in patients

On May 22, 2014, Boehringer Ingelheim announced the next step in the clinical development of idarucizumab, an investigational antidote for rapid reversal of dabigatran-induced anticoagulation. Prior clinical research of the antidote in a healthy volunteer study with 145 participants has already demonstrated its potential for immediate, complete and sustained reversal of the anticoagulant effect of dabigatran. Idarucizumab will now be investigated in the clinical setting in patients taking Pradaxa® (dabigatran etexilate).
Read more on this

Transfusion Medicine Becomes NATA's Official Journal

The NATA board of directors has the pleasure to announce that NATA has entered into a partnership with the British Blood Transfusion Society (BBTS) and that Transfusion Medicine, the official journal of BBTS, edited by Dr. David Roberts, has become NATA's official journal.

Online subscription to Transfusion Medicine is granted to NATA members. Please visit the Members Area for more information.
Read more on this

From the Literature

Aug 28, 2014

Published: Aug 2014

Islam N, Whitehouse M, Mehendale S, et al.

Post-traumatic immunosuppression is reversed by anti-coagulated salvaged blood transfusion: deductions from studying immune status after knee arthroplasty.
Clin Exp Immunol 2014;177:509-520.

#

NATA REVIEW:
This article further explains the potential benefit of reinfused autoogous blood. Since the authors published...
REVIEW by:
D. Thomas

Published: Aug 2014

Bou Monsef J, Figgie MP, Mayman D, Boettner F

Targeted pre-operative autologous blood donation: a prospective study of two thousand and three hundred and fifty total hip arthroplasties.
Int Orthop 2014;38:1591-1595.

#

NATA REVIEW:
Preoperative anaemia is present in 20-40% of patients scheduled for major elective orthopaedic procedures. A...
REVIEW by:
J. A. García-Erce

Published: Aug 2014

Basora M, Tió M, Martin N, et al.

Should all patients be optimized to the same preoperative hemoglobin level to avoid transfusion in primary knee arthroplasty?
Vox Sang 2014;107:148-152.

#

NATA REVIEW:
This is an interesting observational study about the predictors of transfusion in patients undergoing total knee...
REVIEW by:
E. Bisbe

Published: Aug 2014

Bendtsen F, D'Amico G, Rusch E, et al.

Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: An individual patient based meta-analysis of two controlled trials.
J Hepatol 2014;61:252-259.

#

NATA REVIEW:
Recombinant factor VIIa is a potent prohaemostatic agent that is licensed for the treatment of patients with...
REVIEW by:
M. Levi

Published: Jul 2014

Beyer-Westendorf J, Gelbricht V, Forster K, et al.

Peri-interventional management of novel oral anticoagulants in daily care: results from the prospective Dresden NOAC registry.
Eur Heart J 2014;35:1888-1896.

#

NATA REVIEW:
Peri-interventional management of new oral anticoagulants (NOACs) significantly differs from the management of...
REVIEW by:
D. Faraoni

Published: Jul 2014

Looney MR, Roubinian N, Gajic O, et al.

Prospective study on the clinical course and outcomes in transfusion-related acute lung injury.
Crit Care Med 2014;42:1676-1687.

#

NATA REVIEW:
Transfusion-related acute lung injury (TRALI) is a serious complication of blood transfusion and has been the...
REVIEW by:
R. Moog